I must be getting old. I find I can now sit down and read and enjoy high-brow intellectual, philosophical, God-consciousness books and get a lot of good out of them.

Martin Scorsese is teaming up with Apple Original Films again after “Killers of the Flower Moon.” His next project is “Home,” based on a novel by Marilynne Robinson. Scorsese will write ...

Robinson is the author of the Pulitzer Prize-winning “Gilead,” as well as “Home,” “Lila,” “Jack,” “Housekeeping,” “The Givenness of Things,” “The Death of Adam” and more.

Anywho, Robinson’s fictional books, which are some of the best fiction I’ve ever read, are “Gilead,” “Jack,” “Housekeeping,” “Home” and “Lila.” In addition to the Pulitzer ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. U.K drug marketing watchdog the PMCPA ruled the network login process, which directed users to Gilead’s U ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. A group of academics is arguing that countries seeking access ...

In this article, we are going to take a look at where Gilead Sciences Inc. (NASDAQ:GILD) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief ...

In its first quarter 2025 investor letter, ClearBridge Value Strategy emphasized stocks such as Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company.

Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state’s Worker Adjustment and Retraining Notification (WARN ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24 ...

Gilead Sciences (NASDAQ:GILD) had reported double-digit growth in two areas of its commercial products portfolio when it released its Q4 and Full-year 2024 earnings back on February 11th of 2025.